Celiac Disease News and Research

Latest Celiac Disease News and Research

BioLineRx to initiate Phase 1/2 clinical trial on new drug candidate for CML treatment

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that Prof. Arnon Nagler, Director of the Hematology Division and Bone Marrow Transplantation Center at Sheba Medical Center, Israel, has received final regulatory approval to evaluate BioLineRx's BL-8040 as a treatment for chronic myeloid leukemia (CML) in a Phase 1/2 clinical study.

10 Apr 2014

Researchers show Elafin protein plays key role against inflammatory reaction typical of celiac disease

Scientists from INRA and INSERM (France) in collaboration with scientists from McMaster University (Canada) and the Ecole polytechnique fédérale of Zurich (Switzerland) have shown that Elafin, a human protein, plays a key role against the inflammatory reaction typical of celiac disease (gluten intolerance).

8 Apr 2014

Discovery could lead to new therapies for people with celiac disease

Researchers at McMaster University have discovered a key molecule that could lead to new therapies for people with celiac disease, an often painful and currently untreatable autoimmune disorder.

1 Apr 2014

Celiac disease people may have near two-fold increased risk of coronary artery disease

People with celiac disease may have a near two-fold increased risk of coronary artery disease compared with the general population, according to research to be presented at the American College of Cardiology's 63rd Annual Scientific Session.

31 Mar 2014

AJT describes novel approach to long-term tolerance in organ transplantation

REGiMMUNE Corporation announced that the American Journal of Transplantation (AJT) has published its paper that describes a novel approach to long-term tolerance in organ transplantation with continuous administration of immune suppressants.

4 Mar 2014

Avaxia Biologics receives patent for oral anti-TNF antibodies for treatment of IBD

Avaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced today that the company was awarded U.S. Patent No. 8,647,626, entitled "Compositions Comprising TNF-specific Antibodies for Oral Delivery."

12 Feb 2014

Alba Therapeutics reports positive results from Phase IIb trial of larazotide acetate for CeD treatment

Alba Therapeutics Corporation announced today the positive results of their Phase IIb trial evaluating its investigational product, larazotide acetate, a first-in-class tight junction regulator, intended for the treatment of patients with celiac disease (CeD).

11 Feb 2014

BioLineRx's BL-8040 gets FDA Orphan Drug Designation for stem cell mobilization treatment

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received notice from the U.S. Food & Drug Administration confirming an Orphan Drug Designation of BL-8040 as a treatment for stem cell mobilization, in addition to the Orphan Drug Designation previously granted to BL-8040 as a treatment for Acute Myeloid Leukemia.

23 Jan 2014

Adding quinoa to gluten-free diet of patients with celiac disease is well-tolerated

Adding quinoa to the gluten-free diet of patients with celiac disease is well-tolerated, and does not exacerbate the condition, according to new research published in The American Journal of Gastroenterology. Dr. Victor F. Zevallos, from the Department of Gastroenterology, King's College London, United Kingdom, evaluated the in-vivo effects of consuming quinoa in adult celiac patients. Quinoa, a highly nutritious grain, is traditionally recommended as part of a gluten-free diet.

22 Jan 2014

BioLineRx gets approval to begin CE Mark registration trial of BL-5010P for skin lesion treatment

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received approval from the German Federal Institute for Drugs and Medical Devices (BfArM) to commence a pivotal, CE Mark registration trial for BL-5010P, for the non-surgical removal of benign skin lesions.

21 Jan 2014

Genotyping strategy could boost celiac screening efficacy

Genotyping for human leukocyte antigen followed by biopsy is a sensitive strategy for detecting histopathologic lesions in the close relatives of people with celiac disease, research indicates.

24 Dec 2013

Six common diseases arise from DNA changes, finds new research

Many rare disorders are caused by gene mutation, like sickle cell anemia. Yet until now the underlying genetic cause of more common conditions - for example, rheumatoid arthritis - has evaded scientists for years.

22 Dec 2013

BioLineRx enrolls first patient in BL-7010 Phase 1/2 trial for treatment of celiac disease

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today enrollment of the first patient in a Phase 1/2 trial of BL-7010, for the treatment of celiac disease. The first patient was enrolled at Tampere Hospital in Finland, a world-leading site for celiac disease research. Results are expected in mid-2014.

18 Dec 2013

BioLineRx reports promising initial results from Phase 2 trial of BL-8040 in AML patients

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today promising initial results for its BL-8040 drug candidate in a Phase 2 clinical trial for patients with relapsed or refractory acute myeloid leukemia (AML).

16 Dec 2013

Research paper highlights experiences, results of celiac disease screening in young children

Most children who undergo screening to detect gluten intolerance, celiac disease, can handle it well. However, many people feel that the discovery of the disease and the treatment they receive does not provide a better quality of life.

16 Nov 2013

Scientists receive $2.2M grant to improve treatments for immune disorders, inflammatory diseases

Scientists from the Walter and Eliza Hall Institute have been awarded more than $2.2 million from the Australian Research Council (ARC) to improve treatments for immune disorders and inflammatory diseases.

16 Nov 2013

BioLineRx obtains regulatory approval to initiate BL-7010 Phase 1/2 trial for celiac disease

BioLineRx, a biopharmaceutical development company, announced today that it has received regulatory approval from the Finnish National Supervisory Authority for Welfare and Health (Valvira) to commence a Phase 1/2 safety trial for BL-7010, for the treatment of celiac disease.

4 Nov 2013

Researchers develop new interactive software game to help children with peanut allergies

Elizabeth McQuaid, Ph.D., a staff psychologist from the Bradley Hasbro Children's Research Center, is leading a research team testing a new interactive software game developed to help children with peanut allergies better manage allergy symptoms, social situations and proper food avoidance.

24 Oct 2013

Good news: Knowing risk early, women can take action to prevent osteoporosis

On World Osteoporosis Day, October 20, the International Osteoporosis Foundation (IOF) is calling for women to take action now to protect their bone health. Broken bones due to osteoporosis often result in pain, immobility and loss of quality of life as well as early death.

17 Oct 2013

IBS Treatment Center opens new clinic in Santa Monica, California

The IBS Treatment Center, which specializes in treating irritable bowel syndrome, announced the opening of a new clinic in Santa Monica, California, in late October. Conveniently located next to the UCLA Medical Center, this new branch of the clinic will provide a progressive approach to digestive health as well as easy access to treatment for patients previously without adequate care.

15 Oct 2013

Celiac Disease News and Research

Latest Celiac Disease News and Research

BioLineRx to initiate Phase 1/2 clinical trial on new drug candidate for CML treatment

Researchers show Elafin protein plays key role against inflammatory reaction typical of celiac disease

Discovery could lead to new therapies for people with celiac disease

Celiac disease people may have near two-fold increased risk of coronary artery disease

AJT describes novel approach to long-term tolerance in organ transplantation

Avaxia Biologics receives patent for oral anti-TNF antibodies for treatment of IBD

Alba Therapeutics reports positive results from Phase IIb trial of larazotide acetate for CeD treatment

BioLineRx's BL-8040 gets FDA Orphan Drug Designation for stem cell mobilization treatment

Adding quinoa to gluten-free diet of patients with celiac disease is well-tolerated

BioLineRx gets approval to begin CE Mark registration trial of BL-5010P for skin lesion treatment

Genotyping strategy could boost celiac screening efficacy

Six common diseases arise from DNA changes, finds new research

BioLineRx enrolls first patient in BL-7010 Phase 1/2 trial for treatment of celiac disease

BioLineRx reports promising initial results from Phase 2 trial of BL-8040 in AML patients

Research paper highlights experiences, results of celiac disease screening in young children

Scientists receive $2.2M grant to improve treatments for immune disorders, inflammatory diseases

BioLineRx obtains regulatory approval to initiate BL-7010 Phase 1/2 trial for celiac disease

Researchers develop new interactive software game to help children with peanut allergies

Good news: Knowing risk early, women can take action to prevent osteoporosis

IBS Treatment Center opens new clinic in Santa Monica, California

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Celiac Disease News and Research

Latest Celiac Disease News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in